Aquestive Therapeutics In... (AQST)
| Bid | 2.39 |
| Market Cap | 250.14M |
| Revenue (ttm) | 57.56M |
| Net Income (ttm) | -44.14M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -4.96 |
| Forward PE | -5.84 |
| Analyst | Buy |
| Ask | 2.7 |
| Volume | 938,205 |
| Avg. Volume (20D) | 1,615,662 |
| Open | 2.44 |
| Previous Close | 2.47 |
| Day's Range | 2.39 - 2.56 |
| 52-Week Range | 2.20 - 5.80 |
| Beta | 2.59 |
About AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral ...
Analyst Forecast
According to 5 analyst ratings, the average rating for AQST stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 295.26% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells BuyAquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mire...
1 month ago · seekingalpha.com
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call TranscriptAquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S...
